Document:

Employment Agreement, dated September 2, 2002

 Exhibit 10.22 
 Revised 03/02/01 
 

 
 MYRIAD GENETICS, INC. 
 EMPLOYMENT AGREEMENT 
 THIS AGREEMENT is made and entered into by and
between Myriad Genetics, Inc., its wholly-owned subsidiaries, Myriad Genetic Laboratories, Inc. and Myriad Pharmaceuticals, Inc. (hereinafter collectively referred to as “Company’), and Dr JS LANCHBURY (hereinafter referred to as
“Employee”). 
 In consideration of the undersigned’s employment, compensation, and other valuable consideration
and mutual covenants contained herein, the parties agree as follows: 
 1. At Will Employment. Company employs Employee
on an at-will basis, which means that either Employee or the Company can terminate the employment relationship at any time for any reason, with or without notice or cause. Employee’s employment with the Company is not for any particular period
of time. No manager or supervisor of the Company has authority to modify or alter the Company’s at-will employment relationship with Employee, and any statements or promises contrary to at will employment may not be relied upon by Employee.
Employee’s at-will employment with the Company may not be modified or changed in any way, except through a new written employment agreement signed by the President and CEO of the Company and Employee. 

2. Compensation. In consideration for the obligations entered info by Employee, Company initially shall pay Employee in full for
Employee’s services hereunder at the rate of $ 200,000 per year, commencing on the Sept 2nd day of September, 2002. 
 3. Duties. Employee shall at all times faithfully, industriously, and to the best of his/her ability, experience, and talents, perform all of the duties that may be required of him/her pursuant to
the express and implicit terms hereof, to the reasonable satisfaction of the Company. Employee shall not directly or indirectly, in any manner or in any capacity, engage in an outside business endeavor of any kind without the Company’s
expressed written approval, signed by an officer of the Company. 
 4. Inventions or Improvements. Any inventions,
discoveries, know-how, or improvements, which Employee may conceive, make, invent, or develop during his/her employment by the Company, relating to any matter or thing, including but not limited to genetic maps, genes, gene sequences, material
containing a DNA sequence, gene 
 MYRIAD GENETICS. Inc
¿ 320 WAKARA WAY. SALT LAKE CITY. UTAH 84108 ¿
(801) 584-3600 ¿ FAX (801) 584-3640 

 
products, protein molecules, nucleic acid molecules, monoclonal antibodies, pedigrees, genealogy data, germplasm, bacterial artificial chromosomes (BACs), contigs, cell lines, microorganisms,
biologically active compounds, drug screens, processes, and methods of gene identification or gene sequencing that may be connected in any way with Employee’s work or related in any way to Company’s business or Company’s foreseeable
future business, shall be the absolute property of the Company and shall be promptly disclosed to the Company by Employee. Employee agrees that he/she will, at the request of the Company, at any time during the employment or thereafter, assign to
the Company the rights to said inventions and improvements and any patent applications filed or patents granted thereon. 
 5.
Nondisclosure and Nonuse of Information. Employee agrees that during his/her employment and thereafter, he/she will not use or disclose to any person, agency, company, business, or organization, unless authorized by Company, any confidential
or proprietary information concerning Company, including but not limited to any inventions, discoveries, know-how, improvements, processes, products, services, proposals, solicitations, negotiations, customers, manner and method of operations, trade
secrets, business plans, financial information, salary information of other Myriad employees and the like. 
 6.
Noncompetition Agreement. Employee agrees that during the term of his/her employment he/she will not compete with Company either directly or indirectly in any matter or area in which, during the term of his/her employment, Company did or does
business, scientific, technological or product research, development, manufacturing, the providing of services, or marketing (collectively referred to as “business”) or reasonably contemplates that it will do business in the foreseeable
future. Employee agrees that he/she will not use Company’s name, facilities, confidential material, trade secrets, know-how, or privileged information to solicit from any agency, company, business, or organization, work that would result in
income or compensation of any form to Employee or another company or business organization. 
 7. Nonsolicitation
Agreement. 
 a. Nonsolicitation of Customers. During the period of Employee’s employment, and for a period of
two (2) years following voluntary or involuntary termination of employment, Employee will not directly or indirectly solicit the business being provided to the Company by any customer of the Company or any business of any customer of the
Company for use in any activities in competition with activities of the Company, of which Employee acquired knowledge and/or with whom Employee had direct or indirect contact during period of employment relationship with the Company for any purpose
other than to obtain, maintain and/or service the customer’s business for the Company. 

 b. Nonsolicitation of Employees. For a period of two (2) years following
voluntary or involuntary termination of employment with the Company, Employee agrees not to directly or indirectly recruit or solicit any employees of the Company to work for Employee or any other person or company. 

As used above in Sections 7a and 7b, the term “indirectly solicit” includes, but is not limited to, providing names of employees of the
Company, information about employees of the Company, providing Company’s proprietary information to another individual, or entity, and allowing the use of Employee’s name by any company (or any employees of any other company) other than
the Company, in the solicitation of the business of Company’s customers. 
 8. Construction. The parties hereto
agree that the terms of this Agreement shall be construed in accordance with the laws of the State of Utah. 
 9.
Severability. If any provisions hereof should be held invalid, illegal, or unenforceable in any respect in any jurisdiction, then, to the fullest extent permitted by law, all other provisions hereof shall remain in full force and effect in
such jurisdiction and shall be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible. To the extent permitted by applicable law, the parties hereto hereby waive any provision of law that would
render any provisions hereof prohibited or unenforceable in any respect. 
 10. Entire Agreement. This Agreement
supercedes any prior agreement or understandings between Employee and Company with respect to employment, noncompetition, nonsolicitation and nondisclosure, and constitutes the entire agreement between Employee and Company. No modification or
amendment of this Agreement shall be effective unless made in writing and signed by Employee and Company. 
 11.
Representations and Warranties. Employee represents and warrants to the Company that: 
  

	 	a.	All prior confidentiality and non-compete agreements with former employers have been disclosed to the Company. 

 

	 	b.	All proprietary or confidential materials that are the property of a former have been returned to such former employer. 

 

	 	c.	Employment with the Company will not violate any prior confidentiality or non-compete agreements and will not result in misappropriation of another company’s trade
secrets. 

 12. Non-Violation of Prior Agreements. Employee acknowledges that any misuse of a
prior employer’s confidential information or trade secrets, or violation of a prior non-compete agreement, are not authorized by Company and are outside the scope of Employee’s job responsibilities at the Company. 

13. Damages and Injunctive Relief. Employee acknowledges and agrees that any violation of the terms of this Agreement will result
in serious and irreparable damage to Company, and agrees that Company will be entitled to seek appropriate remedies for those damages, including, without limitation, injunctive relief to enforce any provision of this Agreement. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on this 20th day of Sept., 2002. 

 

			
	EMPLOYEE:
		
	Print Name:	 	JS LANCHBURY
	Signature:	 	/s/ JS LANCHBURY
	Position:	 	Senior VP Research

  

			
	COMPANY:
		
	Print Name:	 	Peter D. Meldrum
	Signature:	 	/s/ Peter D. Meldrum
	Position:	 	President & CEONon-Employee Director Compensation Policy

 Exhibit 10.25 
 MYRIAD GENETICS, INC. 
 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

(Effective Fiscal Year 2012) 

The following is a description of the standard compensation arrangements under which our non-employee directors are compensated for their service as
directors, including as members of the various committees of our Board. 
  

			
	 Annual Retainer (all members)
	  	$60,000
		
	 Chairman of the Board
	  	$100,000 additional retainer
		
	 Committee Chair Compensation
	  	
	 Audit Committee
	  	$25,000 additional retainer
	 Compensation Committee
	  	$15,000 additional retainer
	 Nominating and Governance Committee
	  	$15,000 additional retainer
		
	 Committee Member Compensation
	  	
	 Audit Committee (1)
	  	$12,000 additional retainer
	 Compensation Committee (1)
	  	$7,500 additional retainer
	 Nominating and Governance Committee (1)
	  	$7,500 additional retainer
	 Strategic Committee
	  	$5,000 additional retainer

  

	(1)	Other than each Committee Chair 

 Attendance

 Board Meetings: In addition to the annual retainer amounts, we pay each non-employee director a per-meeting cash fee of $2,000 for
attendance at Board meetings in excess of five in-person meetings and four telephonic meetings per fiscal year. 
 Committee Meetings other
than Strategic Committee: We pay each non-employee director a per-meeting cash fee of $2,000 for attendance at committee meetings in excess of four meetings (per each committee), whether in person or telephonic, per fiscal year. 

Strategic Committee: No per meeting fees. 
 All directors are also reimbursed for their out-of pocket expenses incurred in attending meetings. 

Stock Option, Restricted and Unrestricted Stock Grants and Other-Stock-Based Awards 

Under our 2010 Employee, Director and Consultant Equity Incentive Plan (the “2010 Plan”), our non-employee directors may be
awarded stock options, restricted and unrestricted stock grants and/or other stock-based awards. As recommended and determined by our Compensation Committee, and approved by our Board of Directors, on each date of our annual meeting of stockholders,
the Company shall grant to each non-employee director, other than new non-employee directors appointed within six months of the annual meeting, a non-qualified option to purchase 30,000 shares of common stock of the Company, at an exercise price
equal to the closing price of our common stock on the date of grant. 
 In addition, it is our policy to grant a non-qualified
option to purchase 30,000 shares of common stock, at an exercise price equal to the closing price of our common stock on the date of grant, to each new non-employee director upon initial appointment to the Board. 

Options granted to our non-employee directors vest in full upon completion of one full year of service on the Board (generally on the
earlier of the first anniversary of the date of grant or the date of the 

 next annual meeting of stockholders). Options granted to our non-employee directors are exercisable after
the termination of the director’s service on the Board to the extent exercisable on the date of such termination for the remainder of the life of the option. All options granted to our non-employee directors will become fully exercisable upon a
change of control of Myriad or upon their death as provided for under our stock option plan.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]